The Specimen Core provides part of the infrastructure support for Projects 1-4 as well as for future pilot and developmental projects. It has been designed to meet the needs of these projects plus serve as a stand-alone resource for collaborative efforts with other SPOREs. This Core will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. Furthermore, the centralized management of the specimens will facilitate their distribution based upon the priorities defined by a panel of investigators familiar with all of our SPORE research endeavors. There are five central components to this Core: 1. Specimen acquisition, processing, quality control, storage and accessioning into databases. a) Collect, process, store and distribute tissue and serum acquired from patients and controls in the clinic from surgery, and from the rapid autopsy program, with related clinical and pathologic data. b) Prepare DNA, RNA and cDNA, store and distribute to projects c) Perform histological characterization of tissue specimens obtained by the core d) Prepare tissue microarrays for immunohistochemical (IHC) and in situ hybridization (ISH) analyses e) Maintain and expand a prostate cancer specimen repository for potential use by investigators who establish collaborations with the SPORE investigators f) Maintain clinical and selected research results on individual specimens in a relational database. 2. A specimen development program to continually improve the quality of tissue specimens. 3. A prostate cancer xenograft maintenance and development program for comparative tissue studies. 4. Specific services: Interpretation of tissue localization studies by a urologic pathologist, IHC, ISH, RT-PCR and immunoassays, i.e. PSA, and tissue culture. a) Immunohistochemistry and in situ hybridization b) Immunoassays: PSA and other biomarker analyses on serum, plasma or supernatant fluids c) Provide tissue culture support services 5. An administrative program that includes a proactive program of obtaining specimens from minorities, a specimen utilization plan, a quality control program and a program for interactions between SPOREs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA097186-01
Application #
6671826
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-19
Project End
2007-04-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Dai, James Y; Wang, Bo; Wang, Xiaoyu et al. (2018) Vigorous physical activity is associated with metastatic-lethal progression in prostate cancer and differential tumor DNA methylation in the CRACR2A gene. Cancer Epidemiol Biomarkers Prev :
Mateo, Joaquin; Cheng, Heather H; Beltran, Himisha et al. (2018) Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol 73:687-693
Lim, Daniel M; Gulati, Roman; Aleshin-Guendel, Serge et al. (2018) Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate :
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
FitzGerald, L M; Zhao, S; Leonardson, A et al. (2018) Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis 21:228-237
Lee, Chung C W; Munuganti, Ravi Shashi Nayana; Peacock, James W et al. (2018) Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. J Endocr Soc 2:1381-1394
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Bello, Thomas; Gujral, Taranjit S (2018) KInhibition: A Kinase Inhibitor Selection Portal. iScience 8:49-53

Showing the most recent 10 out of 400 publications